Johnson & Johnson is accelerating work on its experimental Ebola vaccine and aims to produce 1 million doses next year, 250,000 of which are expected to be available by May.
Subscribe to Blog via Email
Reader Interactions
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Leave a Reply